Xi'An Yufan Biotechnology Co.,Ltd Report issue

Government Phase 1 Phase 2

Organization Overview

First Clinical Trial
2019
NCT04037566
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Xi'An Yufan Biotechnology Co.,Ltd | Zhuhai Yufan Biotechnologies Co., Ltd

Active Ingredients

Drugs in Phase 2 Trials (1)

prj1-3024 (2 trials)

Drugs in Phase 1 Trials (3)

cyclophosphamide (cytoxan) (1 trial)

fludarabine (fludara) (1 trial)

xyf19 car-t cell (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 1)

Leukemia, Lymphoid (Phase 1)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4